Skip to content
The Nexus
BUSINESSJun 25 · 08:17 UTCTHE RIO TIMESRichard Mann

A Brazilian Ozempic Rival Takes On a $1 Billion Weight-Loss Market

Brazil's Hypera filed to launch Semavy, a semaglutide pen targeting the same drug class as Novo Nordisk's Ozempic. The Brazilian semaglutide market generates at least R$5bn ($960m) annually, and the drug's patent expired in March 2026. Rival EMS already secured approval for a competing product.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
HyperaorganizationSemavyproductNovo NordiskorganizationOzempicproductEMSorganizationsemaglutidetopicBrazilplaceweight-loss markettopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting